Reactive oxygen species-responsive coating based on Ebselen: Antioxidation, pro-endothelialization and anti-hyperplasia for surface modification of cardiovascular stent
Source abstract
Abstract
Atherosclerosis is often accompanied by inflammation and oxidative stress. Excessive reactive oxygen species (ROS) can damage the vascular endothelium, leading to endothelial dysfunction and reduced nitric oxide (NO) bioavailability. Further accumulation of ROS contributes to vascular cell damage, lipid peroxidation, and extracellular matrix deposition. Thus, clearing excess ROS and reshaping the oxidative microenvironment is essential for treating atherosclerosis (AS). In this study, Ebselen, which mimics glutathione peroxidase and possesses redox capabilities, was successfully synthesized. Subsequently, a multifunctional coating was designed using a combination of Ebselen and poly (trimethylene carbonate) (PTMC), capable of protecting cells from ROS-induced damage, promoting vascular endothelialization, and exhibiting anti-proliferative properties. The Ebselen-loaded coating effectively scavenges free radicals (with an elimination rate of 89 %), catalytically releases NO (0.96 × 10⁻¹⁰ to 1.26 × 10⁻¹⁰ mol/cm²/min), and sustainably delivers Ebselen to the lesion site through a redox cycle. Notably, this coating shows excellent hemocompatibility and cytocompatibility. Subcutaneous implantation results indicated that the fibrous capsule thickness of PTMC10 was the lowest, at just 47.7 % of that of PTMC. Therefore, the Ebselen-loaded coating presents promising applications in cardiovascular stents.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Organoselenium and organotellurium chemistry · Cardiovascular, Neuropeptides, and Oxidative Stress Research · Coagulation, Bradykinin, Polyphosphates, and Angioedema
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (69)
Show source-provided references
1. New biomarkers for cardi-ovascular disease
2. A. Dai-ber, Vascular inflammation and oxidative stress: major triggers for cardiovascular disease10.1155/2019/7092151 ↗
3. Polyunsaturated fatty acids and thei-r potential therapeutic role in cardiovascular system disorders-a review10.3390/nu10101561 ↗
4. Cellular senescence and cardiovascular disease-s: moving to the "heart" of the problem10.1152/physrev.00007.2022 ↗
5. A review on coronary artery disease, its risk factors, and therapeutics10.1002/jcp.28350 ↗
6. Nanomaterial co-atings applied on stent surfaces10.2217/nnm-2015-0007 ↗
7. Double coronary artery stent fracture with coronary artery microa-neurysms10.1536/ihj.50.127 ↗
8. Intravascular biore-sorbable polymeric stents: a potential alternative to current drug eluting m-etal stents10.1002/jps.20957 ↗
9. Surface modification of implanted cardiovascular metal stents: from antithrombosis and antirestenosis to endothelialization10.1002/jbm.a.34714 ↗
10. Surface modification of cardiovascular stent material 316l ss with estradiol-loaded poly (trimethy-lene carbonate) film for better biocompatibility10.3390/polym9110598 ↗
11. Recent advances to a-ccelerate re-endothelialization for vascular stents10.1177/2041731417731546 ↗
12. Influences of stent design on in-stent resteno-sis and major cardiac outcomes: a scoping review and meta-analysis10.1007/s13239-021-00569-0 ↗
13. Histopathologic response aft-er hydrophilic polyethylene glycol-coating stent and hydrophobic octadecylt-hiol-coating stent implantations in porcine coronary restenosis model
14. A new category stent with novel polyphosphazene surface modification10.2217/fca-2017-0103 ↗
15. Non-polymer drug-eluting c-oronary stents10.1007/s13346-017-0414-3 ↗
16. Development of in vitro endothelialised stents-review10.1007/s12015-021-10238-3 ↗
17. Controlled slow-release drug-eluting stents for the preventi-on of coronary restenosis: recent progress and future prospects10.1021/acsami.5b01993 ↗
18. Ultra-hydrophilic stent platfo-rms promote early vascular healing and minimise late tissue response: a p-otential alternative to second-generation drug-eluting stents
19. The role of cytokines in t-he development of atherosclerosis10.1134/S0006297916110134 ↗
20. Discovering inflam-mation in atherosclerosis: insights from pathogenic pathways to clinical pra-ctice10.3390/ijms25116016 ↗
21. Acrolein, an environmental to-xicant and its applications to in vivo and in vitro atherosclerosis models: an update10.1016/j.etap.2022.103890 ↗
22. Roles of oxidative stress and inflammation in vascular endothe-lial dysfunction-related disease10.3390/antiox11101958 ↗
23. Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease10.1007/s11883-012-0266-8 ↗
24. The role of oxidative stress in atheroscler-osis10.3390/cells11233843 ↗
25. Comprehensive proteomics of monocytes indicate-s oxidative imbalance functionally related to inflammatory response in chr-onic kidney disease-related atherosclerosis10.3389/fmolb.2024.1229648 ↗
26. α-tocopherol and atherosclerosis10.1177/153537020122600102 ↗
27. Antioxidant properties of anthocyanins and their mechanism of action in atherosclerosis10.1016/j.freeradbiomed.2021.05.040 ↗
28. Bilirubin and endothelial function10.5551/jat.RV17035 ↗
29. A comprehensive review of oxidative stress as the underlying mechanism in atherosclerosi-s and the inefficiency of antioxidants to revert this process10.2174/1381612825666190116103323 ↗
30. Flavonoids: antioxidants against atherosclerosis10.3390/nu2080889 ↗
31. Oxidative stress and vascular disease10.1161/01.ATV.0000150649.39934.13 ↗
32. Roles of vascular oxidative stress and n-itric oxide in the pathogenesis of atherosclerosis10.1161/CIRCRESAHA.116.309326 ↗
33. Inducible nitric oxide synthase: good or bad10.1016/j.biopha.2017.06.036 ↗
34. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice
35. Micelle-embe-dded coating with ebselen for nitric oxide generation10.4103/2045-9912.273955 ↗
36. How to increase cellular glutathione10.3390/antiox12051094 ↗
37. Application of a reactive oxygen species-responsive dr-ug-eluting coating for surface modification of vascular stents10.1021/acsami.1c08880 ↗
38. Ebselen, a useful tool for understanding cellular redox biolog-y and a promising drug candidate for use in human diseases10.1016/j.abb.2015.10.024 ↗
39. A robust mussel-inspired zwitterionic coating on biodegradable poly (L-lactide) stent with enhanced anticoagulant, anti-i-nflammatory, and anti-hyperplasia properties10.1016/j.cej.2021.130910 ↗
40. Ebselen: a r-eview on its synthesis, derivatives, anticancer efficacy and utility in comb-ating sars-cov-210.2174/1389557523666230914103339 ↗
41. Molecular actions of ebselen - an antiinflammatory antioxidant10.1016/0306-3623(95)00003-J ↗
42. Induction of cellular necrosis by the glutathion-e peroxidase mimetic ebselen10.1002/jcb.10500 ↗
43. Ebselen induces apoptosis in HepG2 ce-lls through rapid depletion of intracellular thiols10.1006/abbi.1999.1574 ↗
44. Ebselen inhibits NO-induced apoptosis of differentiated P-C12 cells via inhibition of ASK1-p38 MAPK-p53 and JNK signaling and activation of p44/42 MAPK and Bcl-210.1046/j.1471-4159.2003.02096.x ↗
45. Preferential inhibition of inducible nitric-oxide synthase by ebselen10.1016/0922-4106(94)90179-1 ↗
46. Inhibition by ebselen on nitric oxide mediate-d relaxations in the rat anococcygeus muscle10.1016/S0014-2999(03)01304-9 ↗
47. Site-specific antiatherogenic effect of the antioxid-ant ebselen in the diabetic apolipoprotein e-deficient mouse10.1161/ATVBAHA.109.186619 ↗
48. Lack of glutathione peroxidase-1 facilitates a pro-inflammato-ry and activated vascular endothelium10.1016/j.vph.2015.11.001 ↗
49. Ebselen inhibits p38 mitogen-acti-vated protein kinase-mediated endothelial cell death by hydrogen peroxide10.1016/j.ejphar.2003.11.079 ↗
50. Ebselen: a brief review of its antioxidant capacity and biological applications10.21577/1984-6835.20190132 ↗
51. Synthesis of benzoisoselenazolones via rh (iii)-catalyzed direct annulative selenation by using elemental selenium10.1002/chem.202103485 ↗
52. Ebselen and analogues: pharmacological properties and synthetic strategies for their preparation10.3390/molecules26144230 ↗
53. Cu-catalyzed efficient synthetic methodology for ebselen and related se-n heterocycles10.1021/ol102027j ↗
54. Bilayer vascular grafts with on-demand NO and H2S release capabilities
55. Nitric oxide producing coating mimicking endothelium function for multifunctional vascular stents10.1016/j.biomaterials.2015.06.016 ↗
56. F-abrication of poly (trimethylene carbonate)/reduced graphene oxide-graft-pol-y (trimethylene carbonate) composite scaffolds for nerve regeneration10.1088/1748-605X/ab0053 ↗
57. Preparation and in vit-ro release profiles of drug-eluting controlled biodegradable polymer coating stents10.1016/j.colsurfb.2009.05.016 ↗
58. Oxidative stress, endothelial dysfunction and atherosclerosis10.2174/138161209789058093 ↗
59. Roles for endothelial zinc homeostasis in vascular physiology and coronary artery disease10.1080/10408398.2018.1495614 ↗
60. Vascular oxidative stress, nitric oxide and atherosclerosis10.1016/j.atherosclerosis.2014.09.001 ↗
61. An albumin biopassive polyallylamine film with improved blood compatibility for metal devices10.3390/polym11040734 ↗
62. Improving hemocompatibility and antifouling performance of polyet-hersulfone membrane by in situ incorporation of phosphorylcholine polymer-s10.1016/j.apsusc.2024.159646 ↗
63. Hemocompatibility poly (lactic acid) nanostructures: a bird's eye view
64. Nogo-B regulates endoth-elial sphingolipid homeostasis to control vascular function and blood press-ure10.1038/nm.3934 ↗
65. Cooperative control of blood compatibility and re-endothelializati-on by immobilized heparin and substrate topography10.1016/j.actbio.2014.12.014 ↗
66. Anti-fouling plus: engineered stent c-oating with inflammation-regulation capability enables enhanced tissue heal-ing10.1016/j.compositesb.2023.111055 ↗
67. Influence of endot-helial cells on vascular smooth muscle cells phenotype after irradiation: i-mplication in radiation-induced vascular damages10.2353/ajpath.2006.060116 ↗
68. Vascular oxidant stress e-nhances progression and angiogenesis of experimental atheroma10.1161/01.CIR.0000109698.70638.2B ↗
69. Ebselen inhibits tumor necr-osis factor-α-induced c-Jun N-terminal kinase activation and adhesion mole-cule expression in endothelial cells10.1016/j.yexcr.2003.08.003 ↗